This company has been acquired
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
TCR2 Therapeutics Dividendo
Dividendo criteri di controllo 0/6
TCR2 Therapeutics does not have a record of paying a dividend.
Informazioni chiave
n/a
Rendimento del dividendo
n/a
Rapporto di remunerazione
| Rendimento medio del settore | 1.9% |
| Prossima data di pagamento dei dividendi | n/a |
| Data di stacco del dividendo | n/a |
| Dividendo per azione | n/a |
| Utile per azione | -US$4.15 |
| Previsione del rendimento del dividendo | n/a |
Aggiornamenti recenti sui dividendi
Nessun aggiornamento
Recent updates
Here's Why TCR2 Therapeutics (NASDAQ:TCRR) Must Use Its Cash Wisely
Mar 08
Can TCR2 Therapeutics (NASDAQ:TCRR) Afford To Invest In Growth?
Nov 23TCR² Therapeutics: Betting On A Solid Reversal
Aug 18TCR2 Therapeutics GAAP EPS of -$0.82 misses by $0.02
Aug 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Needs To Drive Business Growth Carefully
Jun 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Can Afford To Drive Business Growth
Jan 11TCR2 Therapeutics: Trading Below Cash
Jan 06TCR2 Therapeutics: Trading Near Cash Value
Oct 12Is There An Opportunity With TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) 26% Undervaluation?
Sep 02TCR2 Therapeutics - Promising Technology And Upside Potential
Jun 15Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Are In A Position To Invest In Growth
Jun 04Who Has Been Selling TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares?
Feb 19
TCR2 Therapeutics (NASDAQ:TCRR) Is In A Good Position To Deliver On Growth Plans
Dec 28TCR2 Therapeutics share slumps 11%, announces response for Phase 1/2 Trial of TC-210
Dec 14TCR2 Therapeutics reports Q3 results
Nov 12TCR² Therapeutics teams up with ElevateBio to expand TC-210 manufacturing capacity
Nov 10Stabilità e crescita dei pagamenti
Recupero dei dati sui dividendi
Dividendo stabile: Insufficient data to determine if TCRR's dividends per share have been stable in the past.
Dividendo in crescita: Insufficient data to determine if TCRR's dividend payments have been increasing.
Rendimento dei dividendi rispetto al mercato
| TCR2 Therapeutics Rendimento dei dividendi rispetto al mercato |
|---|
| Segmento | Rendimento dei dividendi |
|---|---|
| Azienda (TCRR) | n/a |
| Fondo del 25% del mercato (US) | 1.4% |
| Top 25% del mercato (US) | 4.4% |
| Media del settore (Biotechs) | 1.9% |
| Analista previsionale (TCRR) (fino a 3 anni) | n/a |
Dividendo notevole: Unable to evaluate TCRR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Dividendo elevato: Unable to evaluate TCRR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Distribuzione degli utili agli azionisti
Copertura degli utili: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Pagamenti in contanti agli azionisti
Copertura del flusso di cassa: Unable to calculate sustainability of dividends as TCRR has not reported any payouts.